February 01, 2019
SALT LAKE CITY, UT / ACCESSWIRE / February 1, 2019 / ProLung, Inc. (''ProLung'' or the ''Company''), which is focused on reducing the time to diagnosis for lung cancer patients with its ProLung Test™, yesterday announced the preliminary results of its PL-208 Validation Study and outlined its
December 18, 2018
ProLung, Inc. is honored to be named one of the ‘50 leading companies of the year 2018’ by Silicon Review. Furthermore, our interim CEO, Mr. Jared Bauer, is interviewed in their end of the year special issue where he discusses how ProLung is focused on ‘making a difference in time’ for lung cancer
December 13, 2018
SALT LAKE CITY, UT / ACCESSWIRE / December 13, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') is focused on reducing the time to diagnosis for lung cancer patients. ProLung® conducted its 2018 Annual Meeting of Shareholders (''Meeting'') last week with support from many of the individuals
November 21, 2018
SALT LAKE CITY, UT / ACCESSWIRE / November 21, 2018 / ProLung, Inc. ("ProLung" or the "Company") is focused on reducing the time to diagnosis for lung cancer patients. Today ProLung announced final results from its PL-209 repeatability study. The ProLung Test is designed to produce a personalized
October 23, 2018
Consent Solicitation Clearly Failed to Receive the Required Majority - Steven Eror Falsely Claimed Victory for the Third Time SALT LAKE CITY, UT / ACCESSWIRE / October 23, 2018 / ProLung, Inc. ("ProLung" or the "Company") announced today the preliminary results of the consent
October 11, 2018
SALT LAKE CITY, UT / ACCESSWIRE / October 11, 2018 / ProLung, Inc. ("ProLung" or the "Company") today released a letter to its shareholders with an important intellectual property and regulatory update. ProLung® is pleased to announce receipt of a new Notice of Allowance for our proprietary
October 02, 2018
SALT LAKE CITY, UT / ACCESSWIRE / October 2, 2018 / ProLung, Inc. ("ProLung" or the "Company") today disclosed a letter to its stockholders from former ProLung® Board Members Clark Campbell, William Fresh, Rich McKeown, Tim Treu and Dennis Tulane. The complete text of the letter is set forth below.
October 01, 2018
Board In Fact Leads Substantially in the Vote Tally ProLung Urges Shareholders to Continue to Sign and Submit the GOLD Card SALT LAKE CITY, UT / ACCESSWIRE / October 1, 2018 / The board of directors (the “Board”) of ProLung, Inc. (“ProLung” or the “Company”) today issued the following statement in
September 19, 2018
Additions Bring Extensive Operating Experience in Medical Technology and Diagnostics as well as Repeated Success with the FDA Approval Process SALT LAKE CITY, UT / ACCESSWIRE / September 19, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') today announced the appointment of Rob Farnsworth and
September 13, 2018
Dear ProLung Shareholders and Colleagues, I have accepted the position of interim CEO of ProLung, Inc. It is an honor to be given the opportunity to work with each of you and to lead ProLung in its next
